NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
Sumitomo Pharma America, Inc.
Eli Lilly and Company
Eli Lilly and Company
AGC Biologics S.p.A.
Bristol-Myers Squibb